180 Life Sciences Corp (ATNF)
2.15
+0.19
(+9.69%)
USD |
NASDAQ |
Apr 30, 16:00
2.14
-0.01
(-0.47%)
After-Hours: 20:00
180 Life Sciences Cash from Financing (TTM): 5.908M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.908M |
| September 30, 2023 | 10.84M |
| June 30, 2023 | 13.88M |
| March 31, 2023 | 10.92M |
| December 31, 2022 | 10.87M |
| September 30, 2022 | 6.027M |
| June 30, 2022 | 14.27M |
| Date | Value |
|---|---|
| March 31, 2022 | 14.53M |
| December 31, 2021 | 25.41M |
| September 30, 2021 | 14.64M |
| June 30, 2021 | 1.055M |
| March 31, 2021 | 1.295M |
| December 31, 2020 | -8.734M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-8.734M
Minimum
Dec 2020
25.41M
Maximum
Dec 2021
9.300M
Average
10.87M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| Seelos Therapeutics Inc | 11.38M |
| Altimmune Inc | 86.10M |
| GT Biopharma Inc | 6.268M |
| Outlook Therapeutics Inc | 5.120M |
| MAIA Biotechnology Inc | 9.271M |